These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16878109)

  • 21. Tackling corruption in the pharmaceutical systems worldwide with courage and conviction.
    Cohen JC; Mrazek M; Hawkins L
    Clin Pharmacol Ther; 2007 Mar; 81(3):445-9. PubMed ID: 17251983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medication safety issue brief. Counterfeit drug prevention and identification.
    ; ;
    Hosp Health Netw; 2005 Aug; 79(8):29-30. PubMed ID: 16247941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The drug price is right--or is it?
    Siva N
    Lancet; 2009 Apr; 373(9672):1326-7. PubMed ID: 19382291
    [No Abstract]   [Full Text] [Related]  

  • 24. Medicines in Mexico, 1990-2004: systematic review of research on access and use.
    Wirtz VJ; Reich MR; Leyva Flores R; Dreser A
    Salud Publica Mex; 2008; 50 Suppl 4():S470-9. PubMed ID: 19082258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies.
    Hamilton WL; Doyle C; Halliwell-Ewen M; Lambert G
    Health Policy Plan; 2016 Dec; 31(10):1448-1466. PubMed ID: 27311827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of medications on the restricted list by the elderly.
    Vetter NJ; Jones DA; Victor CR
    Br Med J (Clin Res Ed); 1985 Jun; 290(6483):1712-4. PubMed ID: 3924227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The network of official medicines control laboratories].
    Buchheit KH; Wanko R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1139-44. PubMed ID: 25192832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Government intervention in cardiovascular disease--help or hindrance? The pharmaceutical industry viewpoint.
    Marlow HF
    Cardiology; 1994; 85 Suppl 1():102-12. PubMed ID: 7743527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Consumption of prescribed and over-the-counter medicines with prolonged oral clearance used by the elderly in the Northern Region of England, with special regard to generic prescribing, dose form and sugars content.
    Baqir W; Maguire A
    Public Health; 2000 Sep; 114(5):367-73. PubMed ID: 11035458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimum acceptable requirements for introduction and marketing of drugs.
    Lasagna L
    Drugs; 1974; 7(6):409-13. PubMed ID: 4422210
    [No Abstract]   [Full Text] [Related]  

  • 32. Recognition of pharmaceutical prescriptions across the European Union: a comparison of five Member States' policies and practices.
    Miguel LS; Augustin U; Busse R; Knai C; Rubert G; Sihvo S; Baeten R
    Health Policy; 2014 Jun; 116(2-3):206-13. PubMed ID: 24290875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can the selection and use of essential medicines decrease inappropriate drug use?
    Reidenberg MM
    Clin Pharmacol Ther; 2009 Jun; 85(6):581-3. PubMed ID: 19451911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmaceutical prescriptions in Italy.
    Garattini S
    Int J Technol Assess Health Care; 1995; 11(3):417-27. PubMed ID: 7591544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Balancing government regulation against access to drugs: address to Seton Hall University School of Law, February 16, 2007.
    Meron D
    Seton Hall Law Rev; 2007; 37(4):929-39. PubMed ID: 18363219
    [No Abstract]   [Full Text] [Related]  

  • 36. The War on Drugs...or Doctors?
    Kempen PM
    W V Med J; 2017; 113(2):24-5. PubMed ID: 29373006
    [No Abstract]   [Full Text] [Related]  

  • 37. Norway's pivotal role in regulatory health economics and pharmaceutical cost containment--what can other countries learn?
    Andersson F
    Health Policy; 1992 May; 21(1):17-34. PubMed ID: 10171032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Does medicine lose its value near the expiration date?].
    Török I
    Acta Pharm Hung; 2001 Aug; 71(2):213-4. PubMed ID: 11862672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of antimicrobial drug prescription in hospital.
    van der Meer JW; Gyssens IC
    Clin Microbiol Infect; 2001; 7 Suppl 6():12-5. PubMed ID: 11990686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Zealand deserves better. Direct-to-consumer advertising (DTCA) of prescription medicines in New Zealand: for health or for profit?
    Toop L; Richards D; Saunders B
    N Z Med J; 2003 Aug; 116(1180):U556; discussion U556. PubMed ID: 14581976
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.